Moleac.com
  • Home
  • About Us
    • Vision, Values & Mission
    • Milestones
    • Leadership
      • Management Team & Advisors
      • Board of Directors
      • Scientific Advisors & Collaborators
    • Our People, Our Company
    • Responsibility
  • R & D
    • Pipeline
    • Our Strategic Approach
    • Research & Development
    • Publications
  • Products
    • NeuroAiD™II
  • Partners
    • Our Commercial Partners
    • Commercial Partnering Opportunities
    • Research Opportunities
  • News
  • Library
  • Contact Us
  • Career
Select Page
Highlights from Asia Pacific Stroke Organization (APSC) and World Congress of Neurology (WCN) Scientific Symposia

Highlights from Asia Pacific Stroke Organization (APSC) and World Congress of Neurology (WCN) Scientific Symposia

Mar 8, 2022 | News

Highlights from Asia Pacific Stroke Organization (APSC) and World Congress of Neurology (WCN) Scientific Symposia Two scientific symposia were conducted on the 2nd October 2019 and 29th October 2019. Multiple international faculty members shared their perspectives and...
Highlights from European Stroke Organisation Conference (ESOC) Scientific Symposium

Highlights from European Stroke Organisation Conference (ESOC) Scientific Symposium

Mar 8, 2022 | News

Highlights from European Stroke Organisation Conference (ESOC) Scientific Symposium June 2019 A scientific symposium was held on the 24th May 2019, which aimed to share the advance of stroke rehabilitation and the role of NeuroAiD in post-stroke recovery. Clinicians...
Moleac holds two educational symposia on the management of Traumatic Brain Injury

Moleac holds two educational symposia on the management of Traumatic Brain Injury

Mar 8, 2022 | News

Moleac holds two educational symposia on the management of Traumatic Brain Injury March 2019 Moleac organized two symposia in Dubai and Bangkok on new approaches for Traumatic Brain Injury (TBI) recovery. In these symposia, the speakers emphasized on the global burden...
NeuroAiD combined with rehabilitation has shown additive and sustained benefits on post-stroke recovery over 2 years after an initial 3-month treatment following stroke onset

NeuroAiD combined with rehabilitation has shown additive and sustained benefits on post-stroke recovery over 2 years after an initial 3-month treatment following stroke onset

Mar 8, 2022 | News

NeuroAiD combined with rehabilitation has shown additive and sustained benefits on post-stroke recovery over 2 years after an initial 3-month treatment following stroke onset More subjects on NeuroAiD™ improved to functional independence compared to placebo among...
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Stroke Recovery

Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Stroke Recovery

Mar 8, 2022 | News

Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Stroke Recovery SINGAPORE, March 5, 2018 /PRNewswire/ — Moleac, a biopharmaceutical company focused on research and development of new medicines for central nervous...
« Older Entries
Next Entries »

Categories

  • Alzheimer News
  • News
  • Stroke News
  • TBI News

Recent Posts

  • Balancing Risk: New Systematic Review Explores VTE Prophylaxis in Intracranial Hemorrhage Patients
  • Moleac at the Forefront of Stroke Recovery at the 10ᵗʰ Ho Chi Minh Stroke Conference
  • Moleac Joins MCGM 2025 to Support Advancements in Geriatric and Alzheimer’s Care
  • 𝗔𝗦𝗡𝗔 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 | 𝗕𝗮𝗹𝗶, 𝗜𝗻𝗱𝗼𝗻𝗲𝘀𝗶𝗮 | 𝟴 – 𝟭𝟬 𝗔𝘂𝗴𝘂𝘀𝘁 𝟮𝟬𝟮𝟱
  • Meta-Analysis on NeuroAiD’s Role in Stroke Recovery to Be Featured at ASNA 2025

Quick links

Home
About Us
Contact
Privacy Policy
Terms & Conditions

Find us

Moleac Pte Ltd

Contact

  • Helios #09-08, 11 Biopolis Way, Singapore 138667
  • +65 62113710
  • [email protected]

Connect

  • Follow
  • Follow
  • Follow
  • Follow

Copyright © 2003-2025. All Rights Reserved. NeuroAiD by Moleac Pte Ltd, Helios #09-08, 11 Biopolis Way, Singapore 138667

loading

Please wait while you are redirected to the right page...